DNER and anemia (phenotype): One can already foresee a future scenario in which MF patients with more proliferative disease and robust blood counts are treated with ruxolitinib or fedratinib in combination with a BET inhibitor (e.g., CPI-0610) or BH3 mimetic (e.g., navitoclax) and those with anemia receive either momelotinib or one of the currently approved JAK inhibitors in combination with luspatercept, while those with severe thrombocytopenia at baseline are offered pacritinib.